SBRT Clinical Trial
Official title:
A Phase II Study of SBRT Followed by Neoadjuvant Chemoimmunotherapy of Sindilizumab Plus Docetaxel and Cisplatin for Locoregionally Advanced Squamous Carcinoma of Oral Cavity and Oropharynx
In resectable locally advanced oral cavity cancer and oropharyngeal cancer, SBRT with the total dose of 18 Gy by three fractions will be delivered to the primary tumor and metastatic lymph nodes every other day. One week later, neoadjuvant chemoimmunotherapy of Sindilizumab (200mg) plus docetaxel (75mg/m2) and cisplatin (75mg/m2) will be administered every three weeks for three cycles. Then radical surgical resection will be performed and postoperative radiotherapy with or without chemotherapy will be supplemented according to the initial tumor staging and postoperative pathologic characteristics. The investigators aim to evaluate the pathological complete response rate and safety of the combined treatment of SBRT with chemoimmunotherapy in locally advanced cancers of oral cavity and oropharynx.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | December 7, 2026 |
Est. primary completion date | December 7, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - pathologically confirmed squamous carcinoma of oral cavity or oropharynx - III-IVa based on the eighth edition of AJCC - aged 18 to 70 - ECOG PS 0-1 - no organ dysfunction - Expected survival = 3 months Exclusion Criteria: - diagnosed with other malignant tumors - has autoimmune diseases or serious mental illness - at high risk of hemorrhage - Systemic or local glucocorticoid therapy within 4 weeks - Comorbidities requiring long-term treatment with immunosuppressive drugs or systemic or topical corticosteroids in immunosuppressive doses - Patients with active tuberculosis (TB) who are receiving anti-tuberculosis treatment or have received anti-tuberculosis treatment within 1 year prior to screening. - Prior use of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, or anti-CTLA-4 antibody - HIV or HCV - HBsAg positive with positive HBV DNA copy number (quantitative test) =1000cps/ml |
Country | Name | City | State |
---|---|---|---|
China | Sun Yat-sen University Cancer Center | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sun Yat-sen University |
China,
Darragh LB, Knitz MM, Hu J, Clambey ET, Backus J, Dumit A, Samedi V, Bubak A, Greene C, Waxweiler T, Mehrotra S, Bhatia S, Gadwa J, Bickett T, Piper M, Fakhoury K, Liu A, Petit J, Bowles D, Thaker A, Atiyeh K, Goddard J, Hoyer R, Van Bokhoven A, Jordan K, Jimeno A, D'Alessandro A, Raben D, McDermott JD, Karam SD. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. Nat Cancer. 2022 Nov;3(11):1300-1317. doi: 10.1038/s43018-022-00450-6. Epub 2022 Nov 25. Erratum In: Nat Cancer. 2023 Jan;4(1):148. Nat Cancer. 2024 Jan;5(1):210. — View Citation
Ma TM, Wong DJ, Chai-Ho W, Mendelsohn A, St John M, Abemayor E, Chhetri D, Sajed D, Dang A, Chu FI, Xiang M, Savjanji R, Weidhaas J, Steinberg ML, Cao M, Kishan AU, Chin RK. High Recurrence for HPV-Positive Oropharyngeal Cancer With Neoadjuvant Radiation Therapy to Gross Disease Plus Immunotherapy: Analysis From a Prospective Phase Ib/II Clinical Trial. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2):348-354. doi: 10.1016/j.ijrobp.2023.04.029. Epub 2023 May 2. No abstract available. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | rate of pathological complete response | pathological complete response rate after radical resection | immediately after the surgery | |
Secondary | rate of major pathological response | immediately after the surgery | ||
Secondary | objective response rate | two weeks after the chemoimmunotherapy | ||
Secondary | disease free survival | 3-year | ||
Secondary | overall survival | 3-year | ||
Secondary | rate of adverse events | one month after the postoperative radiotherapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04476797 -
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04587817 -
Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors
|
||
Active, not recruiting |
NCT04067570 -
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
|
N/A | |
Recruiting |
NCT02976402 -
Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy
|
Phase 1 | |
Not yet recruiting |
NCT02940990 -
SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations
|
Phase 2 | |
Terminated |
NCT04698915 -
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05817604 -
Stereotactic Body Radiotherapy (SBRT) for Medically Inoperable Localised Renal Tumors (SABINA Trial)
|
||
Active, not recruiting |
NCT04942275 -
Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy
|
Phase 2/Phase 3 | |
Recruiting |
NCT04547452 -
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
|
Phase 2 | |
Completed |
NCT03891472 -
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05344235 -
Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
|